Abstract
Whey-derived growth factor extract (WGFE) and the acid-activated form (WGFE-a) were tested for their ability to influence the migration of cells from chicken flexor tendon biopsies into fibrin clots. When added to the medium surrounding clots, both extracts significantly inhibited migration relative to controls ( P<0.05) in a dose-dependent manner when measurements were made after seven days of incubation. WGFE-a was approximately ten times more potent than WGFE. Since transforming growth factor (TGF)-β1 and -β2 activity of WGFE-a is much higher than in WGFE we hypothesized that TGF-β was responsible for the inhibition of tendon cell migration. Neutralizing anti-TGF-β monoclonal antibody was added to the medium bathing tendon biopsies in fibrin clots along with WGFE-a. WGFE-a alone inhibited migration by 51% and this was reversed by the antibody in a dose-dependent manner. Furthermore, recombinant human TGF-β1 and -β2 significantly inhibited tendon cell migration with similar dose-dependent potency when tested in the assay. These results indicate that TGF-β is largely responsible for the inhibition of tendon cell migration by WGFE-a. This sheds further light on the functions of this growth factor during the early events in tendon repair.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
